The Medical Letter on Drugs and Therapeutics
Tapentadol (Nucynta) - A New Analgesic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 8/11/09: In the pharmacokinetics table, the half-life for tapentadol was changed from "24" to "4".

The FDA has approved tapentadol hydrochloride (Nucynta – Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II controlled substance.

PHARMACOLOGY — Tapentadol is a centrally-acting synthetic oral analgesic; it is, like morphine, a mu-opioid receptor agonist and, like tricyclic antidepressants, a norepinephrine reuptake inhibitor. It has some structural similarity to tramadol (Ultram, and others), which is also an opioid receptor agonist and an inhibitor of norepinephrine (and serotonin) reuptake, but is not classified as a controlled substance by the FDA.1

CLINICAL STUDIES — In a randomized, double-blind trial in 400 patients with moderate to severe postoperative dental pain, total pain relief scores over 8 hours with single doses of tapentadol ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tapentadol (Nucynta) - A New Analgesic
Article code: 1318a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian